Phase II Trial of Pyrazoloacridine in Advanced Non-Small Cell Carcinoma of the Lung: A Kansas Cancer Institute and Thompson Cancer Survival Center Study
| Autor: | Timothy J. Panella, Debbie Graham, Shari L Kretzschmer, Matt Mayo, Stephen K. Williamson, Michael Bastasch |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Male
Pathology medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Antineoplastic Agents Carcinoma Non-Small-Cell Lung Carcinoma medicine Humans Pharmacology (medical) Survival analysis Aged Aged 80 and over Pharmacology Chemotherapy Lung Dose-Response Relationship Drug business.industry Respiratory disease Cancer Middle Aged medicine.disease Survival Analysis Clinical trial medicine.anatomical_structure Oncology Pyrazoloacridine Cancer research Acridines Pyrazoles Female business |
| Zdroj: | Investigational New Drugs. 20:339-342 |
| ISSN: | 1573-0646 0167-6997 |
| DOI: | 10.1023/a:1016293527755 |
| Popis: | More active agents are needed in the treatment of metastatic non-small cell lung cancer. Pyrazoloacridine (PZA) is a 9-methoxy acridine compound containing a reducible 5-nitro substituent. Although the mechanism of action of PZA is unknown, the acridine compounds are known to cause cytotoxicity by interaction with DNA and RNA.Eighteen patients with metastatic non-small cell lung carcinoma were treated with pyrazoloacridine. Pyrazoloacridine was administered as a three-hour infusion at 750 mg/M2 every 21 days.There were no objective responses. One patient maintained stable disease for 20 months. Median survival was 4.8 months. The primary toxicity was granulocytopenia with 5 patients experiencing severe infections.Pyrazoloacridine has no demonstrable activity in patients with metastatic non-small cell carcinoma of the lung when given at this dose and schedule. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink